

## **Pascale Richetta**

**Executive Vice President** 

**Head of the Bone Patient Value Unit** 

Joining UCB on February 1, 2016.

Pascale Richetta joins UCB with over 20 years of experience in the pharma and biotech industry. She has acquired impressive commercial experience managing both traditional pharmaceuticals and complex biologics. Her experience and knowledge of markets around the world is key to helping UCB prepare for future product launches.

Trained as a medical doctor (MD), Pascale Richetta leads UCB's Bone Patient Value Unit. One of her main missions is to take UCB's investigational osteoporosis drug *romosozumab* through the next steps if its development and prepare for its potential launch upon approval.

She is a member of the Executive Committee.

## **Key positions**

Prior to UCB, Pascale held the following positions:

2013 – Present	AbbVie Vice President, Western Europe and Canada In charge of a multi-billion specialty care portfolio including key biologic products Covering 19 affiliates and over 3000 staff
2004 – 2013	Abbott: Vice President, Western Europe and Canada
1994 - 2004	<b>GSK</b> Operations Director in France and Europe in charge of the Central Nervous System franchise
1990-1994	Ipsen Marketing Manager Tanakan®, France
1987-1990	Servier

Product Manager, Stablon®, France

## Education

1985 University of Poitiers, France

M.D.

## Prior trade association engagement

EFPIA: Vice Chair of the Executive Committee, member of the Board

EBE: Member of the Board

EuropaBIO: Member of the Board

Update: January 2016